In contrast, there are no approved therapeutic VLP cancer vaccines, but promising preclinical and early clinical data, mainly in HER-2-positive breast cancer and melanoma treatment, give hope that the goal could be reached. This evidence concerns the gene ERBB2 and breast carcinoma.